id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-P-1617-0006,FDA,FDA-2020-P-1617,Final Response Letter from FDA CDER to E4 Consulting,Other,Denial of Petition,2025-12-12T05:00:00Z,2025,12,2025-12-12T05:00:00Z,,2025-12-12T21:02:24Z,,0,0,09000064b90c915b
FDA-2020-P-1617-0005,FDA,FDA-2020-P-1617,"Determination That BACTROBAN (Mupirocin) Nasal Ointment, 2%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2025-12-12T05:00:00Z,2025,12,2025-12-12T05:00:00Z,,2025-12-12T19:43:45Z,2025-22682,0,0,09000064b90c85b0